XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xeris Biopharma Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.95+0.64 (+6.21%)
Close on Oct 19, 2026
- Market cap
- $1.89B
- P/E (TTM)
- –
- Dividend yield
- –
Xeris Biopharma Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $330.95M | $307.66M | $283.00M | $256.57M | $235.37M | $214.18M | $196.64M | $182.15M | $170.98M | $161.36M | $153.36M | $143.39M | 98.7% | +40.6% |
| Recorlev | $188.86M | $163.52M | $139.28M | $116.56M | $97.31M | $79.21M | $64.28M | $51.47M | $41.84M | $35.67M | $29.55M | $23.55M | 56.3% | +94.1% |
| Gvoke | $93.15M | $94.06M | $94.11M | $92.73M | $90.52M | $87.10M | $82.83M | $78.21M | $73.00M | $68.59M | $67.05M | $63.34M | 27.8% | +2.9% |
| Keveyis | $48.30M | $48.11M | $47.65M | $45.97M | $46.23M | $47.87M | $49.53M | $52.47M | $56.14M | $57.10M | $56.77M | $56.51M | 14.4% | +4.5% |
| Royalty, contract and other revenue | $4.46M | $7.20M | $8.84M | $9.56M | $10.65M | $8.38M | $6.43M | $5.22M | $10.43M | $9.99M | $10.55M | $9.27M | 1.3% | -58.1% |
| Other product revenue | – | – | $1.96M | – | – | – | $0 | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Xeris Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.